Shares of Definium Therapeutics surged 10.2% to $37.65 on October 9 after JPMorgan initiated coverage with an Overweight rating and an $84 price target — implying the stock could more than double from current levels. The call spotlighted the company's lead neuropsychiatry asset, an orally dissolving tablet designed to treat central nervous system disorders, and injected fresh Wall Street credibility into a name that had been drifting lower for a week. JPMorgan Bets Big on Definium's Brain Drug — But Can a Small Biotech Really Double From Here?
Shares of Definium Therapeutics jumped 10.2% to $37.65 on October 9 after JPMorgan initiated coverage with an Overweight rating and an $84 price target — implying substantial upside from current levels. The call from Wall Street's biggest bank lands at a pivotal moment: Definium is a pre-revenue biotech sitting on strong clinical data but burning cash fast, and the question is whether the science justifies a valuation more than double today's price.
JPMorgan's $84 Target Is the Highest on the Street — and It's Not Close
Twenty-two analysts now cover the stock; the consensus rating is "Buy" with an average price target of $66. JPMorgan's $84 figure towers above that average and even tops Robert W. Baird's recently raised target of $79. For shareholders, this kind of high-conviction call from a bulge-bracket bank tends to attract institutional money that smaller firms can't pull in alone.
The Drug's Clinical Results Give the Bull Case Real Teeth Definium's lead compound is a pharmaceutically optimized LSD-derived tablet targeting depression and anxiety. In the Phase 3 Emerge trial for major depression, it showed a statistically significant 8.1-point improvement over placebo on a standard depression scale (p<0.0001).
No serious side effects or suicidality signals were observed.
The FDA granted Breakthrough Therapy designation for the depression indication in September 2026 , adding to an existing Breakthrough designation for anxiety. Piper Sandler has estimated peak U.S. sales potential "well in excess of $3 billion."
The Cash Runway Is Comfortable — For Now
Definium reported roughly $1.1 billion in cash and investments as of June 30, 2026 , bolstered by a June 2026 public offering priced at $34 per share that JPMorgan itself helped underwrite.
Management says current reserves fund operations into 2028. But R&D spending nearly doubled year-over-year to $41.5 million in Q1 alone , and the company has no revenue. Every quarter without an approval widens the gap.
One More Big Data Readout Looms
A second Phase 3 depression trial, Ascend, is expected to deliver results in 2027. If it confirms the first trial's success, Definium could file for FDA approval — turning it from a research story into a potential commercial one. If it disappoints, today's rally unwinds fast. JPMorgan is betting the data holds. At $37.65, so is everyone buying the stock.